Treatment algorithm

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer

ACUTE

tularemia without meningitis

Back
1st line – 

aminoglycoside or ciprofloxacin

The Centers for Disease Control and Prevention (CDC) recommend gentamicin as the drug of choice based on experience and efficacy, particularly for severe cases.[15]​ In other countries, the choice of agent depends on local guidance and availability of these drugs. The World Health Organization (WHO) recommends gentamicin as the drug of choice as it is more widely available, with streptomycin as an alternative if it is available.[17]​​

Fluoroquinolones (e.g., ciprofloxacin) seem to be effective in milder cases of tularemia, although experience with their use is limited.​ The CDC recommends ciprofloxacin as a suitable agent for nonsevere cases of tularemia.​[15][20]​​

Parenteral therapy with an aminoglycoside should be administered to any patient judged with serious enough infection to necessitate hospitalization. Oral therapy with a fluoroquinolone is only advised for outpatient treatment of milder cases.[1]​​​[6]

Treatment course: at least 10 days (aminoglycosides); 10-14 days (ciprofloxacin); longer courses may be required in severe infection depending on the clinical response. Relapse may occur and should be treated with an additional 7 to 14 days of therapy.

Primary options

gentamicin: children: 2.5 mg/kg intravenously/intramuscularly every 8 hours; adults: 5 mg/kg intravenously/intramuscularly every 24 hours

More

Secondary options

ciprofloxacin: children: 15 mg/kg intravenously/orally every 12 hours, maximum 800 mg/day; adults: 400 mg intravenously every 12 hours, or 500 mg orally twice daily

OR

streptomycin: children: 15 mg/kg intramuscularly every 12 hours, maximum 2 g/day; adults: 1 g intramuscularly every 12 hours

More
Back
2nd line – 

doxycycline

Doxycycline is a less-preferred therapy than aminoglycosides or fluoroquinolones because it is bacteriostatic for tularemia, with relapse a potential problem after cessation of therapy. However, the CDC recommends doxycycline as a suitable agent for nonsevere cases of tularemia.[15]​​

Treatment course: 14-21 days. Relapse may occur and should be treated with an additional 7 to 14 days of therapy.

Primary options

doxycycline: children: 2.2 mg/kg intravenously/orally every 12 hours, maximum 200 mg/day; adults: 100 mg intravenously/orally every 12 hours

Back
Consider – 

surgical drainage

Treatment recommended for SOME patients in selected patient group

Surgical drainage of enlarged nodes in ulceroglandular tularemia is frequently required for symptomatic relief.[1]​​

tularemic meningitis

Back
1st line – 

ciprofloxacin plus an aminoglycoside

Although there is little experience to provide guidance, tularemic meningitis should be treated with a combination of ciprofloxacin and an aminoglycoside (e.g., gentamicin, streptomycin). The Centers for Disease Control and Prevention and World Health Organization (WHO) recommend gentamicin first-line for the treatment of severe tularemia.[15][17]​​ The WHO recommends streptomycin as an alternative.​​[17]​​

Treatment should be considered in consultation with an infectious disease specialist.[15]

Treatment course: at least 10-14 days, but depends on the clinical response.

Primary options

ciprofloxacin: children: 15 mg/kg intravenously/orally every 12 hours, maximum 800 mg/day; adults: 400 mg intravenously every 12 hours, or 500 mg orally twice daily

and

gentamicin: children: 2.5 mg/kg intravenously/intramuscularly every 8 hours; adults: 5 mg/kg intravenously/intramuscularly every 24 hours

More

Secondary options

ciprofloxacin: children: 15 mg/kg intravenously/orally every 12 hours, maximum 800 mg/day; adults: 400 mg intravenously every 12 hours, or 500 mg orally twice daily

and

streptomycin: children: 15 mg/kg intramuscularly every 12 hours, maximum 2 g/day; adults: 1 g intramuscularly every 12 hours

More
back arrow

Choose a patient group to see our recommendations

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer

Use of this content is subject to our disclaimer